Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by Millennium Management LLC

Millennium Management LLC increased its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 80.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 192,100 shares of the company's stock after acquiring an additional 85,606 shares during the period. Millennium Management LLC owned about 0.19% of Day One Biopharmaceuticals worth $2,434,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. FMR LLC grew its holdings in Day One Biopharmaceuticals by 73.9% during the fourth quarter. FMR LLC now owns 12,887,467 shares of the company's stock worth $163,284,000 after acquiring an additional 5,475,087 shares during the period. Franklin Resources Inc. grew its holdings in Day One Biopharmaceuticals by 0.3% in the fourth quarter. Franklin Resources Inc. now owns 3,882,952 shares of the company's stock valued at $49,197,000 after purchasing an additional 13,320 shares during the period. Estuary Capital Management LP grew its holdings in Day One Biopharmaceuticals by 35.5% in the fourth quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company's stock valued at $47,092,000 after purchasing an additional 972,997 shares during the period. Pictet Asset Management Holding SA grew its holdings in Day One Biopharmaceuticals by 17.0% in the fourth quarter. Pictet Asset Management Holding SA now owns 3,490,064 shares of the company's stock valued at $44,219,000 after purchasing an additional 507,398 shares during the period. Finally, Alyeska Investment Group L.P. acquired a new stake in Day One Biopharmaceuticals in the fourth quarter valued at approximately $31,829,000. 87.95% of the stock is owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ:DAWN traded up $0.02 during trading on Thursday, reaching $6.95. The stock had a trading volume of 754,559 shares, compared to its average volume of 1,118,877. The business has a fifty day moving average price of $6.95 and a 200-day moving average price of $10.01. The stock has a market cap of $704.47 million, a PE ratio of -6.75 and a beta of -1.30. Day One Biopharmaceuticals, Inc. has a 1-year low of $6.08 and a 1-year high of $16.76.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.11. The company had revenue of $30.76 million for the quarter, compared to analysts' expectations of $30.28 million. Sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. JPMorgan Chase & Co. dropped their price objective on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. The Goldman Sachs Group dropped their price objective on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a report on Tuesday, March 25th. HC Wainwright reissued a "buy" rating and issued a $36.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Needham & Company LLC dropped their price objective on Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Wedbush reissued an "outperform" rating and issued a $25.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Day One Biopharmaceuticals presently has an average rating of "Buy" and a consensus price target of $30.57.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 13,964 shares of Day One Biopharmaceuticals stock in a transaction on Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $87,414.64. Following the sale, the chief executive officer now owns 145,737 shares in the company, valued at $912,313.62. The trade was a 8.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Charles N. York II sold 4,282 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total value of $26,805.32. Following the completion of the sale, the chief financial officer now owns 265,231 shares in the company, valued at $1,660,346.06. This represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,725 shares of company stock worth $167,299. 6.20% of the stock is owned by corporate insiders.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.